Articles Tagged With: Menopause
-
The Proton Pump Inhibitor Use and Hypertension Link in Menopausal Women
In a large study, long-term use of proton pump inhibitors in menopausal women was associated with an increased risk of developing hypertension.
-
Osteoporosis: An Update for Primary Care Providers
Bones, as reservoirs of calcium and phosphorus, continuously remodel to maintain strength and function. However, suboptimal peak bone mass in young adulthood, excessive resorption of bone, or impaired bone formation during remodeling can result in osteoporosis. Among Caucasian adults ages 50 years and older in the United States, about 50% of women and 20% of men will experience an osteoporotic fracture in their remaining lifetime; however, fracture rates differ by ethnic/racial population and skeletal site. Annual fracture-related costs are expected to increase from $57 billion to more than $95 billion by 2040. Therefore, it is imperative that primary care providers address this challenge by implementing practices to screen patients for osteoporosis to prevent and/or treat the disorder and subsequent comorbidities.
-
Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist
A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).
-
How Does the Genitourinary Syndrome of Menopause Affect Patients?
This analysis of baseline questionnaire responses from 302 individuals enrolled in the MsFLASH Vaginal Health Trial demonstrated that the most commonly reported symptoms were vaginal dryness (94%), pain with vaginal penetration (84%), vulvovaginal pain and soreness (76%), and vulvovaginal irritation (73%). The symptom most often rated severe was pain with vaginal penetration (40%).
-
Integrating Reproductive History Could Help Postmenopausal Women’s Long-Term Brain Health
Researchers observed patients with higher cumulative estrogen exposure throughout their life may be at lower risk of developing cerebral small vessel disease.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Fezolinetant Tablets (Veozah)
Fezolinetant can be prescribed to treat moderate-to-severe vasomotor symptoms caused by menopause.
-
Oral Medication to Treat ‘Hot Flashes’ Could Be Available Soon
The FDA has approved the first neurokinin 3 receptor antagonist to alleviate symptoms associated with moderate to severe vasomotor symptoms caused by menopause.
-
Hormonal Contraceptives Help Women Manage Perimenopause
Women near the end of their reproductive years may experience fewer perimenopausal symptoms if they use a hormonal contraceptive, such as a hormonal intrauterine device.